Literature DB >> 27232112

PharmGKB summary: isoniazid pathway, pharmacokinetics.

Daniel J Klein1, Sotiria Boukouvala, Ellen M McDonagh, Scott R Shuldiner, Nicola Laurieri, Caroline F Thorn, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27232112      PMCID： PMC4970941          DOI： 10.1097/FPC.0000000000000232

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  109 in total

1.  A homogenizing process of selection has maintained an "ultra-slow" acetylation NAT2 variant in humans.

Authors:  B Patillon; P Luisi; E S Poloni; S Boukouvala; P Darlu; E Genin; A Sabbagh
Journal:  Hum Biol       Date:  2014       Impact factor: 0.553

2.  Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.

Authors:  Raquel Lima de Figueiredo Teixeira; Renata Gomes Morato; Pedro Hernan Cabello; Ligia Mayumi Kitada Muniz; Adriana da Silva Rezende Moreira; Afrânio Lineu Kritski; Fernanda Carvalho Queiroz Mello; Philip Noel Suffys; Antonio Basilio de Miranda; Adalberto Rezende Santos
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-09       Impact factor: 2.743

3.  Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population.

Authors:  Vinod H Gupta; Meenakshi Singh; Deepak N Amarapurkar; Preetha Sasi; Jyotsna M Joshi; Rajiv Baijal; Praveen Kumar H R; Anjali D Amarapurkar; Kalpana Joshi; Pramod P Wangikar
Journal:  Ann Hepatol       Date:  2013 Nov-Dec       Impact factor: 2.400

4.  Localization of N-acetyltransferases NAT1 and NAT2 in human tissues.

Authors:  K F Windmill; A Gaedigk; P M Hall; H Samaratunga; D M Grant; M E McManus
Journal:  Toxicol Sci       Date:  2000-03       Impact factor: 4.849

5.  Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.

Authors:  Yi-Shin Huang; Wei-Juin Su; Yi-Hsiang Huang; Chih-Yen Chen; Full-Young Chang; Han-Chieh Lin; Shou-Dong Lee
Journal:  J Hepatol       Date:  2007-03-06       Impact factor: 25.083

6.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.

Authors:  Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

7.  Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.

Authors:  Gustavo N O Costa; Luiz A V Magno; Cinthia V N Santana; Cibele Konstantinovas; Samuel T Saito; Moara Machado; Giuliano Di Pietro; Luciana Bastos-Rodrigues; Débora M Miranda; Luiz A De Marco; Marco A Romano-Silva; Fabrício Rios-Santos
Journal:  Mol Diagn Ther       Date:  2012-08-01       Impact factor: 4.074

8.  Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.

Authors:  Hyun-Jung Cho; Won-Jung Koh; Yon-Ju Ryu; Chang-Seok Ki; Myung-Hyun Nam; Jong-Won Kim; Soo-Youn Lee
Journal:  Tuberculosis (Edinb)       Date:  2007-11       Impact factor: 3.131

9.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 10.  CYP2E1 autoantibodies in liver diseases.

Authors:  Salvatore Sutti; Cristina Rigamonti; Matteo Vidali; Emanuele Albano
Journal:  Redox Biol       Date:  2014-11-18       Impact factor: 11.799
View more
  10 in total

1.  PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Authors:  Ankit Balhara; Saranjit Singh
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

2.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021

3.  The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog.

Authors:  Vasiliki Garefalaki; Evanthia Kontomina; Charalambos Ioannidis; Olga Savvidou; Christina Vagena-Pantoula; Maria-Giusy Papavergi; Ioannis Olbasalis; Dionysios Patriarcheas; Konstantina C Fylaktakidou; Tamás Felföldi; Károly Márialigeti; Giannoulis Fakis; Sotiria Boukouvala
Journal:  World J Microbiol Biotechnol       Date:  2019-10-31       Impact factor: 3.312

4.  Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.

Authors:  Mark A Doll; Raúl A Salazar-González; Srineil Bodduluri; David W Hein
Journal:  Acta Pharm Sin B       Date:  2017-06-07       Impact factor: 11.413

5.  Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation.

Authors:  Henrik Cordes; Christoph Thiel; Vanessa Baier; Lars M Blank; Lars Kuepfer
Journal:  NPJ Syst Biol Appl       Date:  2018-02-26

6.  Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines.

Authors:  Abul K Azad; Christopher Lloyd; Wolfgang Sadee; Larry S Schlesinger
Journal:  Front Cell Infect Microbiol       Date:  2020-04-08       Impact factor: 5.293

7.  Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis.

Authors:  Navarat Panjasawatwong; Thanaporn Wattanakul; Richard M Hoglund; Nguyen Duc Bang; Thomas Pouplin; Wichit Nosoongnoen; Vi Nguyen Ngo; Jeremy N Day; Joel Tarning
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

8.  Novel Assay Platform to Evaluate Intracellular Killing of Mycobacterium tuberculosis: In Vitro and In Vivo Validation.

Authors:  Kata Horváti; Kinga Fodor; Bernadett Pályi; Judit Henczkó; Gyula Balka; Gergő Gyulai; Éva Kiss; Beáta Biri-Kovács; Zsuzsanna Senoner; Szilvia Bősze
Journal:  Front Immunol       Date:  2021-11-12       Impact factor: 7.561

Review 9.  Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.

Authors:  Levin Thomas; Arun Prasath Raju; Sonal Sekhar M; Muralidhar Varma; Kavitha Saravu; Mithu Banerjee; Chidananda Sanju Sv; Surulivelrajan Mallayasamy; Mahadev Rao
Journal:  Eur J Clin Pharmacol       Date:  2022-07-19       Impact factor: 3.064

10.  N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.

Authors:  Thuli Mthiyane; James Millard; John Adamson; Yusentha Balakrishna; Cathy Connolly; Andrew Owen; Roxana Rustomjee; Keertan Dheda; Helen McIlleron; Alexander S Pym
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.